A Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients to Test a New Schedule of Efti (IMP321, Eftilagimod Alpha) as Adjunctive to a Weekly Treatment Regimen of Paclitaxel

NCT04252768 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Replaced by other study NCT05747794

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Eftilagimod Alpha
DRUG: Paclitaxel

Sponsor

Immutep S.A.S.